Elekta AB (publ)
STO:EKTA B
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
61.8
87.8794
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Elekta AB (publ)
Elekta AB (publ)
Cost of Revenue
Elekta AB (publ)
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elekta AB (publ)
STO:EKTA B
|
Cost of Revenue
-kr11.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
S
|
Surgical Science Sweden AB
STO:SUS
|
Cost of Revenue
-kr269.6m
|
CAGR 3-Years
-82%
|
CAGR 5-Years
-72%
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Cost of Revenue
-kr243.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-13%
|
|
|
Getinge AB
STO:GETI B
|
Cost of Revenue
-kr17.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Cost of Revenue
-kr6.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Cost of Revenue
-kr247.8m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-17%
|
|
Elekta AB (publ)
Glance View
Elekta AB operates as a medical technology company. The company is headquartered in Stockholm, Stockholm and currently employs 4,591 full-time employees. The firm offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The firm has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The firm owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).
See Also
What is Elekta AB (publ)'s Cost of Revenue?
Cost of Revenue
-11.3B
SEK
Based on the financial report for Apr 30, 2024, Elekta AB (publ)'s Cost of Revenue amounts to -11.3B SEK.
What is Elekta AB (publ)'s Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-8%
Over the last year, the Cost of Revenue growth was -8%. The average annual Cost of Revenue growth rates for Elekta AB (publ) have been -12% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
